Ciltacabtagene autoleucel
- Generic Name:
- Ciltacabtagene autoleucel
- Drug Type:
- B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy
- How the Drug is Given:
Suspension for intravenous infusion
- Names:
- Carvykti™
- Ciltacabtagene autoleucel
Indications and Usage
Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Side effects needing medical attention
The most common nonlaboratory adverse reactions are fever, cytokine release syndrome, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections-pathogen unspecified, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia (rapid heartrate), dizziness, dyspnea (difficulty breathing), edema (Puffiness caused by excess fluid trapped in the body's tissues), viral infections, coagulopathy (bleeding disorder), constipation, and vomiting. The most common laboratory adverse reactions include thrombocytopenia, neutropenia, anemia, aminotransferase elevation and hypoalbuminemia.